Position in LLY
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$1,670,806
+$197,335 QoQ
Shares Held
1,393
-13.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.70%
of 13F equity value
Holder Rank
#2,664
of 4,605 holders
Holding Since
Sep 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Derivatives in LLY
reported options exposure · as of Mar 31, 2026CallValue
$15,636
CallShares
17
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $3,050,095 across 6 Drug Manufacturers - General names. LLY ranks #1 (54.8% of the industry book) .
All Filings in LLY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,670,806 | 1,393 | Shares | Defined | 2026-07-08 | |
| 2026-03-31 | $15,636 | 17 | Call | Defined | 2026-04-15 | |
| 2026-03-31 | $1,473,471 | 1,602 | Shares | Defined | 2026-04-15 | |
| 2025-12-31 | $1,480,909 | 1,378 | Shares | Defined | 2026-01-16 | |
| 2025-09-30 | $1,038,443 | 1,361 | Shares | Defined | 2025-12-15 | |
| 2025-06-30 | $887,105 | 1,138 | Shares | Defined | 2025-07-30 | |
| 2025-03-31 | $173,441 | 210 | Shares | Defined | 2025-04-17 | |
| 2024-09-30 | $3,743,982 | 4,226 | Shares | Sole | 2024-10-18 | |
| 2024-03-31 | $155,592 | 200 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $210,434 | 361 | Shares | Defined | 2024-01-12 | |
| 2022-09-30 | $58,526 | 181 | Shares | Defined | 2022-10-19 | |
| No filing history on record for this holder in this stock. | ||||||